Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

X-Waiver Exemption in the Treatment of Opioid Use Disorder

X-Waiver Exemption in the Treatment of Opioid Use Disorder Letters patient or physician biases make randomization to invasive ranged from 53% to 75% among 16 315 patients with stage I vs noninvasive therapies difficult, and planned studies have NSCLC who received lobectomy, depending on tumor size and failed to accrue patients (STARS [NCT00840749], ROSEL visceral pleural invasion status. [NCT00687986], and ACOSOG [NCT01336894]). A UK feasi- The USPSTF found a smaller body of evidence on the bility study concluded that a phase 3 trial of surgery vs SABR benefits of SBRT, with more varied outcomes reported. For was not possible due to patient preferences to undergo SABR example, in a propensity score–matched analysis of other- when presented both options. Nevertheless, 2 studies, wise healthy patients with operable lung cancer receiving STABLE-MATES (NCT02468024) and VALOR (NCT02984761), lobectomy or SBRT in the National Cancer Database, the are ongoing to address this question. 5-year overall survival rate was 29% among 1781 patients Given the efficacy of SABR as a potential curative treat- receiving SBRT. In the same study, 235 patients who under- ment and the importance of shared decision-making be- went SBRT after refusing surgery were propensity score tween patients and physicians, the USPSTF should consider matched with lobectomy patients and had http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

X-Waiver Exemption in the Treatment of Opioid Use Disorder

JAMA , Volume 326 (5) – Aug 3, 2021

Loading next page...
 
/lp/american-medical-association/x-waiver-exemption-in-the-treatment-of-opioid-use-disorder-5JVoFL1z90
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.8267
Publisher site
See Article on Publisher Site

Abstract

Letters patient or physician biases make randomization to invasive ranged from 53% to 75% among 16 315 patients with stage I vs noninvasive therapies difficult, and planned studies have NSCLC who received lobectomy, depending on tumor size and failed to accrue patients (STARS [NCT00840749], ROSEL visceral pleural invasion status. [NCT00687986], and ACOSOG [NCT01336894]). A UK feasi- The USPSTF found a smaller body of evidence on the bility study concluded that a phase 3 trial of surgery vs SABR benefits of SBRT, with more varied outcomes reported. For was not possible due to patient preferences to undergo SABR example, in a propensity score–matched analysis of other- when presented both options. Nevertheless, 2 studies, wise healthy patients with operable lung cancer receiving STABLE-MATES (NCT02468024) and VALOR (NCT02984761), lobectomy or SBRT in the National Cancer Database, the are ongoing to address this question. 5-year overall survival rate was 29% among 1781 patients Given the efficacy of SABR as a potential curative treat- receiving SBRT. In the same study, 235 patients who under- ment and the importance of shared decision-making be- went SBRT after refusing surgery were propensity score tween patients and physicians, the USPSTF should consider matched with lobectomy patients and had

Journal

JAMAAmerican Medical Association

Published: Aug 3, 2021

References